Portfolio

Selecta Biosciences

Selecta Biosciences, Inc. is a clinical-stage biotechnology company developing novel drugs that use immune modulating nanomedicines to generate targeted antigen-specific immune responses to prevent and treat disease. Selecta’s proprietary Synthetic Vaccine Particle (SVP) platform creates a novel paradigm in immunotherapeutics and vaccines, enabling completely new applications while offering the potential of improved efficacy and safety profiles.

In July 2016, Selecta raised a $74M IPO.

Back

Company Profile

Selecta Biosciences Logo

Flagship Partners:

  • Ed Kania, Managing Partner